Durability of antidepressant response to vagus nerve stimulation (VNS).

Departments of Biological Psychiatry , New York State Psychiatric Institute, New York, NY 10032, USA.
The International Journal of Neuropsychopharmacology (Impact Factor: 5.26). 01/2008; 10(6):817-26. DOI: 10.1017/S1461145706007425
Source: PubMed

ABSTRACT This study characterized the durability of improvement in patients who responded early or late while receiving vagus nerve stimulation (VNS). In both a pilot and pivotal study, patients were identified who had at least a 50% reduction in symptom scores 3 months (early responders) or 12 months (late responders) after starting VNS. Probabilities were determined for maintenance of response at 12-month and 24-month time-points. Consistency of improvement throughout the 24-month study period was evaluated, testing for change in serial depression ratings. In the pilot study, 30.5%, 23.7% and 45.8% were early responders, later responders, and non-responders, respectively. These rates were 14.6%, 19.5%, and 65.9% in the pivotal trial. The potential confound of alterations in antidepressant treatment was examined in the pivotal trial. In the pilot study, 72.2% and 61.1% of early responders (n=18) were responders at 12 and 24 months, respectively; 78.8% of late responders (n=14) were responders at 24 months. In the pivotal trial, of early responders (n=30), 63.3% and 76.7% maintained response at 12 and 24 months, respectively; of late responders (n=40), 65.0% maintained response at 24 months. Early and late responders had fewer changes in medication than non-responders across the pivotal study period. In both studies, analyses of serial depression ratings showed stable improvement in early and late responders. These samples had exceptional levels of chronicity and treatment resistance. Yet patients who showed substantial clinical benefit maintained the improvement at remarkably high rates. This durability of benefit was not attributable to alterations in other treatments.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Geriatric depression is associated with increased mortality because of suicide and decreases in functional and physical health. Many elders' depression is resistant to psychotherapy and medication and can become chronic. Electroconvulsive therapy (ECT) is increasingly used in the treatment of medication-resistant or life-threatening geriatric depression. Neuromodulation therapies (subconvulsive, focal, or subconvulsive and focal) are alternatives for the management of treatment-resistant depression in the elderly. Therapies that combine both strategies could be safer but may not be as effective as ECT. This review covers the evidence on the safety and efficacy of ECT and the neuromodulation therapies in geriatric depression.
    The Psychiatric clinics of North America 12/2013; 36(4):607-630. · 1.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Depression is the most common psychiatric comorbidity in epilepsy patients. The lack of success with current pharmacological interventions for this patient population, highlights the importance of optimizing non-pharmacological neuromodulatory treatments such as vagus nerve stimulation (VNS). Studies on the antidepressant effect of VNS in epilepsy patients may be confounded by concurrent antiepileptic drug therapy. To date, studies in epilepsy models overcoming this problem are lacking. Objective We investigated whether VNS affects anhedonia, a key symptom of major depression, in the kainic acid rat model for temporal lobe epilepsy. Methods Anhedonia was assessed in kainic acid (KA) and saline (SAL) injected rats using the saccharin preference test (SPT). To exclude differences in taste perception, the quinine aversion test (QAT) was performed. Both groups were randomly subdivided in a VNS and a SHAM group, yielding 4 experimental arms: KA-VNS, KA-SHAM, SAL-VNS and SAL-SHAM. Both VNS groups received 2 weeks of VNS, while the SHAM groups were not stimulated. Thereafter, the SPT and QAT were repeated. Results Saccharin preference was significantly reduced in the KA compared to the SAL rats (p<0.05), without differences in quinine aversion. Two weeks of VNS significantly increased the saccharin preference in the KA-VNS group (p<0.05), while it had no effect on quinine aversion. No effects of VNS or SHAM were found in the other groups. Conclusion The KA rats displayed anhedonia which was significantly decreased by VNS, indicating that this neuromodulatory treatment could likewise diminish depressive symptoms in patients suffering from temporal lobe epilepsy and comorbid depression.
    Brain Stimulation 09/2014; · 5.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aimthe purpose of this study is to evaluate the efficacy of Vagus Nerve Stimulation (VNS) as a therapeutic option for Treatment-Resistant Depression (TRD), with a follow-up period of 1, 3 and 5 years after VNS surgery. Methodswe examined 27 consecutive patients with unipolar TRD. Depressive symptoms were evaluated both at baseline and at follow-up after the surgery by means of the Hamilton Rating Scale for Depression, 21 items (HAM-D 21). ResultsThe mean HAM-D preoperative score was of 25.6. Twenty-two patients were evaluated after 1 year of treatment, and the mean improvement of HAM-D score was of 10.3. Five patients (20%) went into complete remission (HAM-D
    Psychiatry and Clinical Neurosciences 02/2014; · 2.04 Impact Factor